

# FREDUN PHARMACEUTICALS LIMITED

*Compassionate Healthcare*



CIN No : L24239MH1987PLC043662

Date: 13<sup>th</sup> February 2017

To,

Listing Department,  
Bombay Stock Exchange,  
Dalal Street Fort,  
Mumbai - 400001

Subject: Un-audited Financial Results for the Quarter and Nine months ended 31<sup>st</sup> December 2016 and the Limited Review Report.

Dear Sir,

Enclosed herewith are :-

The Un-audited Financial Results for the Quarter and Nine months ended 31<sup>st</sup> December 2016 duly approved by the Board of Directors of the Company at their Meeting held on the 13<sup>th</sup> February 2017 along with the Limited Review Report as issued by the Statutory Auditors of the Company.

Thanking you

Yours Faithfully

**For FREDUN PHARMACEUTICALS LIMITED**

*to medhan*

**DIRECTOR**

# FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662



## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2016

Rs. In Lacs

PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended
	Unaudited			Unaudited		Audited
	31.12.2016	30.09.2016	31.12.2015	31.12.2016	31.12.2015	31.03.2016
<b>1 Income from Operations</b>						
a) Net Sales /Income From Operation (Net of Excise Duty)	1250.40	1033.67	1251.34	3933.97	2649.45	4232.13
b) Other Operating Income	138.67	3.74	42.12	159.98	69.42	86.18
Total income from operations (net)	1389.07	1037.41	1293.46	4093.95	2718.87	4318.31
<b>2 Expenses</b>						
a) Cost of Material Consumed	958.10	760.23	964.30	2527.55	1931.27	3042.33
b) Purchases of stock -in-trade	0.00	0.00	29.63	0.00	75.07	82.84
c) Changes in inventories of finished goods, work-in-progress and stock in trade	(92.22)	(211.36)	(106.66)	123.00	(264.85)	(442.05)
d) Employees benefits expenses	136.63	103.31	78.91	339.51	254.94	382.56
e) Depreciation and amortisation expenses	22.64	22.64	13.66	65.39	40.98	80.43
f) Other Expenses	314.24	275.51	230.59	788.12	481.08	776.02
Total expenses	1339.39	950.33	1210.43	3843.57	2518.49	3922.13
3 costs and exceptional item (1-2)	49.68	87.08	83.03	250.38	200.38	396.18
4 Other income	0.00	0.00	0.00	0.00	0.00	0.00
5 Profit/(Loss) from ordinary activities before financial costs and exceptional item (3+4)	49.68	87.08	83.03	250.38	200.38	396.18
6 Less : Finance Cost	35.63	53.08	52.26	126.61	122.33	205.93
7 before exceptional item (5-6)	14.05	34.00	30.77	123.77	78.05	190.25
8 Exceptional items	0.00	(1.21)	0.00	(1.21)	0.00	(6.75)
9 Profit/(Loss) from ordinary activities before tax (7-8)	14.05	32.79	30.77	122.56	78.05	183.50
10 Tax Expenses	0.00	0.00	3.00	15.00	10.00	76.55
11 Net Profit/(Loss) from ordinary activities after tax (9-10)	14.05	32.79	27.77	107.56	68.05	106.95
12 Extraordinary item (net of tax expenses)	0.00	0.00	0.00	0.00	0.00	0.00
13 Net Profit/(Loss) for the period (11-12)	14.05	32.79	27.77	107.56	68.05	106.95
14 Paid up Equity Share Capital (Face Value of Rs-10/- each)	237.45	237.45	237.45	235.24	237.45	235.24
15 Reserves excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00	133.53
16 Earning per Share (EPS) (before & after extra ordinary items) - Basic/ Diluted Earning Per Share (Rs.)	0.59	1.38	1.17	4.57	2.86	4.55
<b>A 1) Public Shareholding</b>						
Number of shares	601290	601290	601290	601290	601290	601290
Percentage of shareholding	25.56	25.56	25.56	25.56	25.56	25.56
<b>2) Promoters and promoter group shareholding</b>						
a) Pledged/Encumbered						
- Number of shares			-		-	-
Promoters and Prompter Group) Company)			-		-	-
b) Non-encumbered						
- Number of shares	1751110	1751110	1751110	1751110	1751110	1751110
Promoters and Prompter Group) Company)	100%	100%	100%	100%	100%	100%
	74.44	74.44	74.44	74.44	74.44	74.44

### NOTES :-

- 1) The above results were taken on record by the Board of Directors at the meeting held on 13.02.2017
- 2) Previous year's figures have been regrouped/rearranged wherever necessary.
- 3) There are no investor's complaints pending & no investor's complaints were received by the company.
- 4) The auditors of the company have carried out Limited Review of the aforesaid results.

PLACE : MUMBAI

DATE : 13.02.2017

FOR FREDUN PHARMACEUTICALS LIMITED

*Manoj Medhankar*

DIRECTOR

Manoj Industrial Premises, G.D.Ambekar Marg, Wadala, Mumbai - 400 031, (INDIA)

Phone : 91-22 - 4031 8111 Fax : 91-22-40318133 E-mail : business@fredungroup.com Web : www.fredungroup.com





# Savla & Associates

CHARTERED ACCOUNTANTS

8/196, Guru Sevak Kutir, Station Road

Wadala (W) MUMBAI - 400 031.

PHONE : 24102526, 24112526 FAX : 24132121

## LIMITED REVIEW REPORT

### TO THE BOARD OF DIRECTORS OF FREDUN PHARMACEUTICALS LTD

26,Manoj Industries Premises,  
G.P.Ambekar marg, Wadala,  
Mumbai – 400 031.

1. We have reviewed the accompanying Statement of Unaudited standalone Financial Result of **FREDUN PHARMACEUTICALS LTD** for the Quarter ended December 31, 2016 except for the disclosures regarding 'Public Shareholding' and Promoter Group Shareholding which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Financial Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of Company personal and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the Stock Exchanges, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR SAVLA & ASSOCIATES

Chartered Accountants

(Firm Registration No.109361W)



KINJAL R. SAWLA

(Partner)

Membership No. : 134603

MUMBAI, February 13, 2017

